Since the introduction of the Pill over 60 years ago, combined hormonal contraception (CHC) has remained one of the most popular forms of contraception. This article outlines the choice of CHC available, including different formulations of the combined oral contraceptive pill, the transdermal patch and the vaginal ring, and discusses the benefits and risks associated with their use.
{"title":"Benefits and risks of combined hormonal contraception","authors":"Jenny Kitson","doi":"10.1002/psb.1994","DOIUrl":"https://doi.org/10.1002/psb.1994","url":null,"abstract":"Since the introduction of the Pill over 60 years ago, combined hormonal contraception (CHC) has remained one of the most popular forms of contraception. This article outlines the choice of CHC available, including different formulations of the combined oral contraceptive pill, the transdermal patch and the vaginal ring, and discusses the benefits and risks associated with their use.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"23 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72490731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hepatitis C is an insidious disease of the liver caused by infection with the hepatitis C virus. Part 1 in this two‐part series on the management of hepatitis C focuses on its epidemiology, routes of transmission and clinical presentation.
{"title":"Hepatitis C: epidemiology, transmission and presentation","authors":"G. Parsons","doi":"10.1002/psb.1992","DOIUrl":"https://doi.org/10.1002/psb.1992","url":null,"abstract":"Hepatitis C is an insidious disease of the liver caused by infection with the hepatitis C virus. Part 1 in this two‐part series on the management of hepatitis C focuses on its epidemiology, routes of transmission and clinical presentation.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84822402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Spending time in conversation with patients helps them to become well informed and active participants in the therapeutic partnership. Angus Thompson describes how analogies and imagery can sometimes be useful to help patients understand the purpose of their medicines and the reasons behind treatment decisions.
{"title":"Helping patients to understand their medicines","authors":"A. Thompson","doi":"10.1002/psb.1996","DOIUrl":"https://doi.org/10.1002/psb.1996","url":null,"abstract":"Spending time in conversation with patients helps them to become well informed and active participants in the therapeutic partnership. Angus Thompson describes how analogies and imagery can sometimes be useful to help patients understand the purpose of their medicines and the reasons behind treatment decisions.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81551795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The GINA Global Strategy for Asthma Management and Prevention was updated in 2021 in light of new evidence. This article summarises the treatment recommendations and how they might predict the awaited new UK‐wide guidance from NICE, BTS and SIGN.
{"title":"Updated GINA guidance on the management of chronic asthma","authors":"S. Chaplin","doi":"10.1002/psb.1984","DOIUrl":"https://doi.org/10.1002/psb.1984","url":null,"abstract":"The GINA Global Strategy for Asthma Management and Prevention was updated in 2021 in light of new evidence. This article summarises the treatment recommendations and how they might predict the awaited new UK‐wide guidance from NICE, BTS and SIGN.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81077917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Inclisiran (Leqvio) is a double‐stranded, siRNA cholesterol‐lowering agent for the treatment of primary hypercholesterolaemia or mixed dyslipidaemia. This article discusses its mode of action, efficacy and place in therapy.
{"title":"Inclisiran: an siRNA to treat hypercholesterolaemia","authors":"S. Chaplin","doi":"10.1002/psb.1986","DOIUrl":"https://doi.org/10.1002/psb.1986","url":null,"abstract":"Inclisiran (Leqvio) is a double‐stranded, siRNA cholesterol‐lowering agent for the treatment of primary hypercholesterolaemia or mixed dyslipidaemia. This article discusses its mode of action, efficacy and place in therapy.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72697214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Glaucoma is the leading cause of irreversible blindness and the aim of all glaucoma treatments is to lower intraocular pressure (IOP), the only modifiable risk factor. This article summarises the identification and management of open‐angle and closed‐angle glaucoma, including medical, laser and surgical treatment options.
{"title":"Identification and management of glaucoma","authors":"Sunil Mamtora, Duncan Leadbetter, D. Atan","doi":"10.1002/psb.1985","DOIUrl":"https://doi.org/10.1002/psb.1985","url":null,"abstract":"Glaucoma is the leading cause of irreversible blindness and the aim of all glaucoma treatments is to lower intraocular pressure (IOP), the only modifiable risk factor. This article summarises the identification and management of open‐angle and closed‐angle glaucoma, including medical, laser and surgical treatment options.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"6 8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75415077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ofatumumab (Kesimpta) is a new anti‐CD20 monoclonal antibody therapy for the treatment of relapsing‐remitting multiple sclerosis. This article outlines its properties, efficacy and adverse effects.
{"title":"Ofatumumab for the treatment of relapsing‐remitting MS","authors":"S. Chaplin","doi":"10.1002/psb.1987","DOIUrl":"https://doi.org/10.1002/psb.1987","url":null,"abstract":"Ofatumumab (Kesimpta) is a new anti‐CD20 monoclonal antibody therapy for the treatment of relapsing‐remitting multiple sclerosis. This article outlines its properties, efficacy and adverse effects.","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75383859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"What does the future hold for prescribers?","authors":"","doi":"10.1002/psb.1981","DOIUrl":"https://doi.org/10.1002/psb.1981","url":null,"abstract":"","PeriodicalId":88184,"journal":{"name":"The Prescriber","volume":"116 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79356379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：